Portal Vein Thrombosis: Baveno VII Consensus Recommendations for                     Diagnosis and Management

Bozzato, Alessandro M.; Bruno, Onorina; Payance, Audrey; Plessier, Aurelie; Chouard, Amelie; Rautou, Pierre-Emmanuel; Vilgrain, Valerie; Ronot, Maxime

doi:10.1148/rg.230128

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the uniqueness of the portal venous system, the increased risk of thrombosis in the portal system could be attributed to the splanchnic territory in LC [ 3 ]. PVT is more commonly diagnosed in its advanced stages [ 4 ], with its incidence increasing by up to 25% in liver transplantation candidates and 35% in patients with hepatocellular carcinoma (HCC) [ 5 ]. The prevalence of PVT in patients with LC varied widely in reported studies, ranging from 0.6% to 15.8% [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis

Suzuki,

Namisaki,

Takya

et al. 2024

IJMS

View full text Add to dashboard Cite

Portal vein thrombosis (PVT), one of the most prevalent hepatic vascular conditions in patients with liver cirrhosis (LC), is associated with high mortality rates. An imbalance between a disintegrin-like metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS-13) enzyme and von Willebrand factor (VWF) is responsible for hypercoagulability, including spontaneous thrombus formation in blood vessels. Herein, we aimed to identify potential prognostic and diagnostic biomarkers in Japanese patients with LC and PVT. In total, 345 patients were divided into two groups: 40 patients who developed PVT (PVT group) and 305 who did not develop PVT (NPVT group). Among the 345 patients with LC, 81% (279/345) were deemed ineligible due to the presence of preventive comorbidities, active or recent malignancies, and organ dysfunction. The remaining 66 patients were divided into two groups: the PVT group (n = 33) and the NPVT group (n = 33). Plasma ADAMTS-13 activity (ADAMTS-13:AC) and the vWF antigen (VWF:Ag) were measured using enzyme-linked immunosorbent assays. Contrast-enhanced, three-dimensional helical computed tomography (CT) was used to detect and characterize PVT. ADAMTS-13:AC was significantly lower in the PVT group than in the NPVT group. No significant differences in plasma vWF:Ag or liver stiffness were observed between the two groups. ADAMTS-13:AC of <18.8 was an independent risk factor for PVT on multivariate analyses (odds ratio: 1.67, 95% confidence interval: 1.21–3.00, p < 0.002). The receiver operating characteristic analysis of ADAMTS-13:AC revealed an area under the curve of 0.913 in PVT detection. Patients with PVT having ADAMTS-13:AC ≥18.8 (n = 17) had higher albumin levels and better prognoses than those with ADAMTS-13:AC <18.8 (n = 16). No significant correlations of ADAMTS-13:AC levels with either fibrin degradation product or D-dimer levels were observed. ADAMTS-13:AC levels could be potential diagnostic and prognostic biomarkers for PVT in Japanese patients with LC.

show abstract

Section: Introductionmentioning

confidence: 99%

ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis

Suzuki,

Namisaki,

Takya

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Imagerie des maladies vasculaires hépatiques

Vilgrain

2024

Imagerie Du Foie

View full text Add to dashboard Cite

Transjugular Intrahepatic Portosystemic Shunts for Acute and Chronic Portal Vein Thrombosis in Preparation for Liver Transplant

Novelli,

Leo,

Orons

2024

Digestive Disease Interventions

View full text Add to dashboard Cite

The presence of portal vein thrombosis (PVT) in the pre-liver transplant patient can significantly impact waitlist, peri- and posttransplant outcomes, morbidity, and mortality. This article describes the pathophysiology of PVT and treatment options in patients with cirrhosis. It defines indications and rationale for placing transjugular intrahepatic portosystemic shunts, emphasizing technical details and risks in patients with nonneoplastic PVT awaiting liver transplantation.

show abstract

Portal Vein Thrombosis: Baveno VII Consensus Recommendations for Diagnosis and Management

Cited by 3 publications

References 6 publications

ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis

ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis

Imagerie des maladies vasculaires hépatiques

Transjugular Intrahepatic Portosystemic Shunts for Acute and Chronic Portal Vein Thrombosis in Preparation for Liver Transplant

Contact Info

Product

Resources

About